Research programme: anti-angiogenesis peptides - Affymax/EntreMed

Drug Profile

Research programme: anti-angiogenesis peptides - Affymax/EntreMed

Latest Information Update: 27 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affymax; EntreMed
  • Class Peptides
  • Mechanism of Action Angiogenesis inhibitors; VLDL receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Dec 2008 Preclinical development is ongoing in USA
  • 16 Jan 2006 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top